Form 4: Artelo Biosciences Director Reyes Gregory Amends Stock Option Terms
SEC Form 4
Director Reyes Gregory amended the terms of several stock options in Artelo Biosciences, including repricing and revesting, as part of a company-wide offer.
Summary
- On February 28, 2024, Director Reyes Gregory amended the terms of several stock options in Artelo Biosciences (ARTL).
- The amendments include repricing and revesting of certain eligible options as part of a company offer.
- The director's holdings include options with exercise prices ranging from $1.55 to $15.
- Some options vest monthly, while others vest on the anniversary of the vesting commencement date or the date prior to the annual meeting of stockholders.
- The repricing and revesting offer was approved by the Issuer's Compensation Committee of the Board of Directors.
Sentiment
Score: 6
Explanation: The document is neutral, detailing routine stock option amendments. It doesn't contain overtly positive or negative information.
Positives
- The repricing and revesting offer may incentivize the director to remain with the company.
- The vesting schedules provide a mechanism for long-term alignment of interests between the director and the company.
Risks
- The value of the options is dependent on the future performance of Artelo Biosciences' stock.
- Changes in the company's stock price could impact the value of the options and the director's motivation.
Industry Context
Stock option grants and amendments are common practices in the biotechnology industry to incentivize and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages in the biotech industry, similar to companies like Amgen, Gilead Sciences, and Biogen.
- Vesting schedules, such as monthly or anniversary-based vesting, are also common practices to ensure long-term commitment from employees and directors.
Stakeholder Impact
- The stock option amendments could potentially impact shareholder value depending on the future performance of the company.
- The amendments are designed to incentivize the director, which could benefit the company and its stakeholders.
Key Dates
| Date | Description |
|---|---|
| 12/04/2020 | Original grant date for some stock options with vesting commencement date. |
| 06/23/2022 | Original grant date for some stock options. |
| 06/24/2022 | Original grant date for some stock options. |
| 08/10/2022 | 1-for-15 reverse stock split. |
| 06/30/2023 | Vesting Commencement Date for some stock options. |
| 08/04/2023 | Vesting Commencement Date for some stock options. |
| 02/28/2024 | Date of transaction (amendment of stock options). |
| 03/01/2024 | Date of signature. |
| 12/04/2030 | Expiration date for some stock options. |
| 07/16/2031 | Expiration date for some stock options. |
| 06/24/2032 | Expiration date for some stock options. |
| 06/30/2033 | Expiration date for some stock options. |
| 08/04/2033 | Expiration date for some stock options. |
Keywords
stock options, Artelo Biosciences, director, Reyes Gregory, repricing, revesting, amendment, equity incentive plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.